Demographic and transplant-related characteristics of the study cohort
| Parameter . | All (n = 54) . |
|---|---|
| Recipient age at HSCT, y (median, IQR) | 57 (62) |
| Recipient genre (M:F) | 37:17 |
| Donor age, y (median, IQR) | 41 (21.5) |
| Donor genre (M:F) | 39:15 |
| Underlying diagnosis, n (%) | |
| AML | 27 (50) |
| ALL | 4 (7.4) |
| AL nonspecific | 2 (3.7) |
| CML/CLL | 2 (3.7) |
| Lymphoma | 4 (7.5) |
| Myeloma | 1 (1.9) |
| MDPS/MDS/MPS | 12 (22.2) |
| Hemoglobinopathy | 2 (3.7) |
| Donor type, n (%) | |
| MUD | 22 (40.7) |
| MMUD | 2 (3.7) |
| MRD | 9 (16.7) |
| Haploidentical | 21 (38.9) |
| First transplantation, n (%) | 49 (90.7) |
| Conditioning with ATG, n (%) | 39 (72.2) |
| PTCy, n (%) | 22 (40.7) |
| No T-cell depletion, n (%) | 53 (98.1) |
| Cryopreservation, n (%) | 43 (79.6) |
| Stem cell source, n (%) | |
| BM | 3 (5.5) |
| PBSC | 51 (94.4) |
| CMV serostatus, n (%) | |
| D+/R+ | 22 (40.7) |
| D–/R+ | 12 (22.2) |
| D+/R– | 7 (13) |
| D–/R– | 13 (24.1) |
| Disease risk index, n (%) | |
| Low | 4 (7.4) |
| Intermediate | 41 (75.9) |
| High/very high | 7 (13) |
| NA | 2 (3.7) |
| Parameter . | All (n = 54) . |
|---|---|
| Recipient age at HSCT, y (median, IQR) | 57 (62) |
| Recipient genre (M:F) | 37:17 |
| Donor age, y (median, IQR) | 41 (21.5) |
| Donor genre (M:F) | 39:15 |
| Underlying diagnosis, n (%) | |
| AML | 27 (50) |
| ALL | 4 (7.4) |
| AL nonspecific | 2 (3.7) |
| CML/CLL | 2 (3.7) |
| Lymphoma | 4 (7.5) |
| Myeloma | 1 (1.9) |
| MDPS/MDS/MPS | 12 (22.2) |
| Hemoglobinopathy | 2 (3.7) |
| Donor type, n (%) | |
| MUD | 22 (40.7) |
| MMUD | 2 (3.7) |
| MRD | 9 (16.7) |
| Haploidentical | 21 (38.9) |
| First transplantation, n (%) | 49 (90.7) |
| Conditioning with ATG, n (%) | 39 (72.2) |
| PTCy, n (%) | 22 (40.7) |
| No T-cell depletion, n (%) | 53 (98.1) |
| Cryopreservation, n (%) | 43 (79.6) |
| Stem cell source, n (%) | |
| BM | 3 (5.5) |
| PBSC | 51 (94.4) |
| CMV serostatus, n (%) | |
| D+/R+ | 22 (40.7) |
| D–/R+ | 12 (22.2) |
| D+/R– | 7 (13) |
| D–/R– | 13 (24.1) |
| Disease risk index, n (%) | |
| Low | 4 (7.4) |
| Intermediate | 41 (75.9) |
| High/very high | 7 (13) |
| NA | 2 (3.7) |
AL, acute leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, antithymocyte globulin; BM, bone marrow; CLL, chronic lymphoblastic leukemia; CML, chronic myeloid leukemia; MDPS, myelodysplastic/myeloproliferative syndrome; MDS, myelodysplastic syndrome; MMUD, mismatched unrelated donor; MPS, myeloproliferative syndrome; MRD, matched related donor; MUD, matched unrelated donor; PBSC, peripheral blood stem cells; PTCy, posttransplant cyclophosphamide.